1. Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection
- Author
-
Barbara Altieri, Anna La Salvia, Roberta Modica, Francesca Marciello, Olaf Mercier, Pier Luigi Filosso, Bertrand Richard de Latour, Dario Giuffrida, Severo Campione, Gianluca Guggino, Elie Fadel, Mauro Papotti, Annamaria Colao, Jean-Yves Scoazec, Eric Baudin, Antongiulio Faggiano, University of Würzburg = Universität Würzburg, 'Federico II' University of Naples Medical School, Hôpital Marie-Lannelongue, Università degli studi di Torino = University of Turin (UNITO), CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Catania = University of Catania (Unict), Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), This research was funded by POR Campania FESR 2014-2020 and 'RARE.PLAT.NET' CUP B63D18000380007 (to A.C.)., Altieri, Barbara, La Salvia, Anna, Modica, Roberta, Marciello, Francesca, Mercier, Olaf, Luigi Filosso, Pier, Richard de Latour, Bertrand, Giuffrida, Dario, Campione, Severo, Guggino, Gianluca, Fadel, Elie, Papotti, Mauro, Colao, Annamaria, Scoazec, Jean-Yve, Baudin, Eric, and Faggiano, Antongiulio
- Subjects
lcnec ,[SDV]Life Sciences [q-bio] ,Medicine (miscellaneous) ,adjuvant therapy ,age ,lymph nodes ,neuroendocrine tumor ,prognosis ,prognostic marker ,pulmonary cancer ,surgery ,survival ,lymph node ,prognosi - Abstract
International audience; Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44–83), were included. Lobectomy (69.2%), bilobectomy (5.1%), pneumonectomy (18%), and wedge resection (7.7%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9% of cases. After a median follow-up of 44 (4–169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0%, 54.6%, and 44.9%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95%CI = 1.46–12.07, p = 0.008 and HR = 13.56, 95%CI 2.45–74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95%CI 2.23–38.83, p = 0.002 and HR = 11.88, 95%CI 2.28–61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy. © 2023 by the authors.
- Published
- 2023
- Full Text
- View/download PDF